{"id":"hib-conjugate-vaccine","safety":{"commonSideEffects":[{"rate":"5-30","effect":"Local injection site reactions (erythema, swelling, pain)"},{"rate":"1-5","effect":"Fever"},{"rate":"5-10","effect":"Irritability or fussiness"},{"rate":"5-10","effect":"Drowsiness"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains the polysaccharide capsule of Haemophilus influenzae type b conjugated to a protein carrier (such as diphtheria toxoid or meningococcal protein), which enhances immunogenicity and T-cell dependent responses. This conjugation allows the vaccine to elicit both antibody production and immunological memory, providing protection against invasive Hib disease including meningitis, epiglottitis, and bacteremia.","oneSentence":"The Hib conjugate vaccine stimulates the immune system to produce antibodies against Haemophilus influenzae type b by conjugating the bacterial polysaccharide capsule to a protein carrier.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:36.136Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive Haemophilus influenzae type b disease (meningitis, epiglottitis, bacteremia, pneumonia)"},{"name":"Routine childhood immunization"}]},"trialDetails":[{"nctId":"NCT02140047","phase":"PHASE2","title":"Exploratory Clinical Study of MT-2301","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2014-04","conditions":"Haemophilus Influenza Type b","enrollment":154},{"nctId":"NCT07160244","phase":"PHASE3","title":"BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-25","conditions":"Healthy","enrollment":6000},{"nctId":"NCT06663436","phase":"PHASE2","title":"A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-11-13","conditions":"Diarrhoea","enrollment":200},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT07354269","phase":"PHASE4","title":"Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-09-26","conditions":"Poliomyelitis","enrollment":180},{"nctId":"NCT06647407","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-05","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":750},{"nctId":"NCT02992925","phase":"PHASE3","title":"Phase 3 Study of BK1310 in Healthy Infants","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2016-11","conditions":"Immunization; Infection","enrollment":370},{"nctId":"NCT07320716","phase":"PHASE2","title":"Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-01-02","conditions":"Diarrhoea","enrollment":528},{"nctId":"NCT03891758","phase":"PHASE3","title":"Confirmatory Study of BK1310 in Healthy Infants","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2019-04-01","conditions":"Tetanus, Diphtheria, Pertussis","enrollment":267},{"nctId":"NCT07203755","phase":"PHASE1","title":"Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine","status":"RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2025-12-19","conditions":"Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis, Haemophilus Influenzae Type B Infection","enrollment":260},{"nctId":"NCT05073003","phase":"PHASE1","title":"A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-06","conditions":"Diarrhoea","enrollment":551},{"nctId":"NCT04429295","phase":"PHASE3","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-06-28","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation","enrollment":460},{"nctId":"NCT05091619","phase":"PHASE3","title":"A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed","status":"ACTIVE_NOT_RECRUITING","sponsor":"China National Biotec Group Company Limited","startDate":"2021-10-22","conditions":"Whooping Cough, Diphtheria, Tetanus","enrollment":2898},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT06621654","phase":"PHASE1","title":"Clinical Trial of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-11-15","conditions":"Haemophilus Influenzae Type B Infection","enrollment":160},{"nctId":"NCT06947499","phase":"PHASE2, PHASE3","title":"A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series","status":"RECRUITING","sponsor":"LG Chem","startDate":"2025-05-30","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":1186},{"nctId":"NCT05951725","phase":"PHASE3","title":"A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2023-08-11","conditions":"Diphtheria, Tetanus and Acellular Pertussis","enrollment":2520},{"nctId":"NCT03547271","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-12-14","conditions":"Meningococcal Infections","enrollment":1660},{"nctId":"NCT03566940","phase":"PHASE2","title":"A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2018-07-31","conditions":"Healthy","enrollment":302},{"nctId":"NCT06748612","phase":"PHASE4","title":"Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV)","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-01-28","conditions":"Polio","enrollment":1190},{"nctId":"NCT03574389","phase":"PHASE3","title":"A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-06-23","conditions":"Pneumococcal Infections, Pneumococcal Conjugate Vaccine","enrollment":936},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT06605755","phase":"NA","title":"Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old Infants","status":"RECRUITING","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2024-09-05","conditions":"Pertussis, Diphtheria, Tetanus","enrollment":785},{"nctId":"NCT04535037","phase":"PHASE4","title":"A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-05-26","conditions":"Diphtheria","enrollment":500},{"nctId":"NCT03691610","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-04","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":950},{"nctId":"NCT04978818","phase":"PHASE4","title":"Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children (the HibVax Study)","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2022-01-27","conditions":"Haemophilus Influenzae Type B Infection","enrollment":333},{"nctId":"NCT06344065","phase":"PHASE3","title":"Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants","status":"RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2023-12-21","conditions":"Healthy Volunteers","enrollment":1584},{"nctId":"NCT03530124","phase":"PHASE4","title":"Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines","status":"COMPLETED","sponsor":"Duke University","startDate":"2018-07-17","conditions":"Apnea, Apnea Neonatal, Prematurity","enrollment":223},{"nctId":"NCT06213506","phase":"PHASE2","title":"A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-01-15","conditions":"Salmonella Infections","enrollment":516},{"nctId":"NCT06184542","phase":"PHASE1","title":"Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine","status":"RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2023-12-23","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":460},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT03630705","phase":"PHASE3","title":"Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":525},{"nctId":"NCT05457946","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2023-04-01","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":1438},{"nctId":"NCT03180359","phase":"NA","title":"Vaccines Immunogenicity in Renal, Hepatic, Cardiac or Pulmonary Transplanted Children","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2016-01-01","conditions":"Transplantation","enrollment":55},{"nctId":"NCT03620162","phase":"PHASE3","title":"A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-18","conditions":"Pneumococcal Infections","enrollment":900},{"nctId":"NCT04099303","phase":"PHASE1","title":"Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed .","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2020-04-28","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":400},{"nctId":"NCT02447718","phase":"PHASE4","title":"Vaccinating Children After Chemotherapy","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2015-11-16","conditions":"Acute Lymphoblastic Leukemia","enrollment":156},{"nctId":"NCT01129362","phase":"","title":"Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-02-08","conditions":"Pertussis","enrollment":1195},{"nctId":"NCT00855855","phase":"","title":"Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-02","conditions":"Haemophilus Infections, Diphtheria, Tetanus","enrollment":20830},{"nctId":"NCT03205371","phase":"PHASE3","title":"Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-11-07","conditions":"Meningitis, Meningococcal","enrollment":1183},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT01436396","phase":"PHASE3","title":"Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-09-07","conditions":"Dengue, Dengue Hemorrhagic Fever, Yellow Fever","enrollment":792},{"nctId":"NCT01411241","phase":"PHASE3","title":"Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-07-18","conditions":"Dengue, Dengue Hemorrhagic Fever","enrollment":720},{"nctId":"NCT05095844","phase":"","title":"National Vaccine Adverse Event Reporting Survey and Etiology","status":"UNKNOWN","sponsor":"Neuroganics LLC","startDate":"2022-03-15","conditions":"COVID-19, Vaccine Adverse Reaction, Vaccine Reaction","enrollment":100000},{"nctId":"NCT04865497","phase":"PHASE2","title":"Immunogenicity and Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 3 Months to 5 Years Old","status":"COMPLETED","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2019-01-19","conditions":"Dysentery, Dysentery, Bacillary","enrollment":1050},{"nctId":"NCT02482636","phase":"PHASE2","title":"Baby Vaccine Study (Sched3)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-08","conditions":"Infectious Diseases","enrollment":189},{"nctId":"NCT01144663","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-01","conditions":"Infections, Meningococcal, Meningococcal Vaccines","enrollment":2095},{"nctId":"NCT03207750","phase":"PHASE3","title":"This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-14","conditions":"Rotavirus Infection, Rotavirus Vaccines","enrollment":1280},{"nctId":"NCT01896596","phase":"PHASE4","title":"Hepatitis B Vaccination in Infants","status":"COMPLETED","sponsor":"Public Health England","startDate":"2013-07","conditions":"Meningococcal Disease, Pneumococcal Disease, Haemophilus Influenzae Serotype b Disease","enrollment":300},{"nctId":"NCT01453998","phase":"PHASE2","title":"Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-10-14","conditions":"Acellular Pertussis, Hepatitis B, Haemophilus Influenzae Type b","enrollment":657},{"nctId":"NCT00454987","phase":"PHASE4","title":"Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05-16","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis, Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine","enrollment":288},{"nctId":"NCT00136604","phase":"PHASE3","title":"Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-22","conditions":"Whole Cell Pertussis, Haemophilus Influenzae Type b, Hepatitis B","enrollment":617},{"nctId":"NCT00228917","phase":"PHASE3","title":"Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-06-16","conditions":"Whole Cell Pertussis, Tetanus, Hepatitis B","enrollment":798},{"nctId":"NCT01171989","phase":"PHASE2","title":"Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08-18","conditions":"Tetanus, Diphtheria, Haemophilus Influenzae Type b","enrollment":391},{"nctId":"NCT01577732","phase":"PHASE3","title":"Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-12-08","conditions":"Acellular Pertussis, Haemophilus Influenzae Type b, Tetanus","enrollment":321},{"nctId":"NCT00489554","phase":"PHASE3","title":"Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-03","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae Vaccines","enrollment":230},{"nctId":"NCT00352963","phase":"PHASE3","title":"Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-09-30","conditions":"Poliomyelitis, Tetanus, Acellular Pertussis","enrollment":480},{"nctId":"NCT00814710","phase":"PHASE3","title":"Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03-07","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae","enrollment":360},{"nctId":"NCT00609492","phase":"PHASE3","title":"Evaluate Safety and Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine in Preterm Born Infants.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-01-03","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae Vaccines","enrollment":245},{"nctId":"NCT00463437","phase":"PHASE3","title":"Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-25","conditions":"Hepatitis B, Acellular Pertussis, Tetanus","enrollment":1437},{"nctId":"NCT01353703","phase":"PHASE3","title":"Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-04-16","conditions":"Poliomyelitis, Tetanus, Acellular Pertussis","enrollment":224},{"nctId":"NCT01153841","phase":"PHASE3","title":"Primary Vaccination Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Vietnam","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-17","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae Vaccines","enrollment":300},{"nctId":"NCT01545375","phase":"PHASE2","title":"Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-05-21","conditions":"Infections, Streptococcal","enrollment":1806},{"nctId":"NCT02207816","phase":"PHASE3","title":"An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-18","conditions":"Malaria","enrollment":3084},{"nctId":"NCT00678301","phase":"PHASE3","title":"Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-06-18","conditions":"Infections, Streptococcal","enrollment":365},{"nctId":"NCT02097472","phase":"PHASE1, PHASE2","title":"Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers","status":"COMPLETED","sponsor":"PATH","startDate":"2014-04","conditions":"Pneumonia, Pneumococcal","enrollment":304},{"nctId":"NCT00866619","phase":"PHASE3","title":"Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03-27","conditions":"Malaria","enrollment":15459},{"nctId":"NCT02858440","phase":"PHASE3","title":"A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-09-13","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":235},{"nctId":"NCT04073459","phase":"PHASE2","title":"Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2019-11","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":336},{"nctId":"NCT04056728","phase":"PHASE4","title":"A Phase IV Study to Assess the Safety of EupentaTM Inj","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2019-09-23","conditions":"Hepatitis B, Diphtheria, Haemophilus Influenzae Type B Infection","enrollment":3000},{"nctId":"NCT02712177","phase":"","title":"Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of Immunization","status":"COMPLETED","sponsor":"CHU de Quebec-Universite Laval","startDate":"2008-08","conditions":"Meningococcal Infections","enrollment":4535},{"nctId":"NCT00466947","phase":"PHASE3","title":"COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-28","conditions":"Infections, Streptococcal","enrollment":23802},{"nctId":"NCT02422264","phase":"PHASE4","title":"Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-01-22","conditions":"Acellular Pertussis, Tetanus, Poliomyelitis","enrollment":601},{"nctId":"NCT01098474","phase":"PHASE2","title":"Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-07","conditions":"Tuberculosis","enrollment":301},{"nctId":"NCT00652951","phase":"PHASE3","title":"Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-04-01","conditions":"Infections, Streptococcal","enrollment":780},{"nctId":"NCT00370396","phase":"PHASE3","title":"Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09-25","conditions":"Infections, Streptococcal","enrollment":1200},{"nctId":"NCT01204658","phase":"PHASE2","title":"Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09-27","conditions":"Infections, Streptococcal","enrollment":576},{"nctId":"NCT01235949","phase":"PHASE4","title":"Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-11-12","conditions":"Infections, Streptococcal","enrollment":850},{"nctId":"NCT03931239","phase":"NA","title":"The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 Weeks","status":"COMPLETED","sponsor":"Vabiotech","startDate":"2018-03-01","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":222},{"nctId":"NCT01341639","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-05-26","conditions":"Bacterial Infections, Virus Diseases","enrollment":1250},{"nctId":"NCT01480258","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-11-23","conditions":"Bacterial Infections, Virus Diseases","enrollment":1315},{"nctId":"NCT01553279","phase":"PHASE3","title":"Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2012-03-30","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":284},{"nctId":"NCT00625677","phase":"PHASE4","title":"Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life","status":"COMPLETED","sponsor":"Public Health England","startDate":"2008-02","conditions":"Meningococcal Infections, Pneumococcal Infections","enrollment":130},{"nctId":"NCT00503165","phase":"PHASE4","title":"A Phase IV Study to Evaluate the Immunogenicity and Safety in UK Laboratory Workers of Menitorix","status":"COMPLETED","sponsor":"Public Health England","startDate":"2007-07","conditions":"Vaccination","enrollment":30},{"nctId":"NCT00625118","phase":"","title":"A Study to Gather Safety Data Following Administration of a Hib-containing Booster Vaccine in Children Aged Two to Five Years","status":"COMPLETED","sponsor":"Public Health England","startDate":"2007-12","conditions":"Haemophilus Infections","enrollment":500},{"nctId":"NCT01839188","phase":"PHASE3","title":"Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2013-05-01","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":385},{"nctId":"NCT01003418","phase":"PHASE2","title":"Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-11-17","conditions":"Influenza","enrollment":8},{"nctId":"NCT01323647","phase":"PHASE3","title":"Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously Vaccinated Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-04-25","conditions":"Poliomyelitis","enrollment":957},{"nctId":"NCT01777308","phase":"PHASE3","title":"Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-05-03","conditions":"Infections, Meningococcal","enrollment":156},{"nctId":"NCT00496015","phase":"PHASE3","title":"Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-02","conditions":"Infections, Streptococcal","enrollment":750},{"nctId":"NCT00345358","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09-18","conditions":"Infections, Streptococcal","enrollment":600},{"nctId":"NCT00547248","phase":"PHASE3","title":"Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-22","conditions":"Infections, Streptococcal","enrollment":756},{"nctId":"NCT00513409","phase":"PHASE2","title":"Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08-22","conditions":"Infections, Streptococcal","enrollment":163},{"nctId":"NCT00390910","phase":"PHASE3","title":"Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10-01","conditions":"Infections, Streptococcal","enrollment":286},{"nctId":"NCT00344318","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-08-07","conditions":"Infections, Streptococcal","enrollment":806},{"nctId":"NCT01340937","phase":"PHASE3","title":"A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-05-10","conditions":"Bacterial Infections, Virus Diseases","enrollment":2808},{"nctId":"NCT01337167","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-04-19","conditions":"Bacterial Infections, Virus Diseases","enrollment":1473},{"nctId":"NCT02002156","phase":"PHASE4","title":"A Study of the Interaction Between BCG And MenC Immunisation: BAM","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2014-06-20","conditions":"BCG Infection, Reaction - Vaccine, Immune Response","enrollment":28},{"nctId":"NCT00310856","phase":"PHASE2","title":"Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2005-06","conditions":"Meningococcal Meningitis","enrollment":175}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":299,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Hib conjugate vaccine","genericName":"Hib conjugate vaccine","companyName":"Public Health England","companyId":"public-health-england","modality":"Biologic","firstApprovalDate":"","aiSummary":"The Hib conjugate vaccine stimulates the immune system to produce antibodies against Haemophilus influenzae type b by conjugating the bacterial polysaccharide capsule to a protein carrier. Used for Prevention of invasive Haemophilus influenzae type b disease (meningitis, epiglottitis, bacteremia, pneumonia), Routine childhood immunization.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}